Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 10/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 10/20 | 0.37 |
| ▸ | BRD2 | P25440 | 9/20 | 0.37 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16259901 | 0.81 | ALDH1A1 (0.41) | BRD4BRD3BRD2CREBBPMAPT | |
| SCHEMBL16244304 | 0.78 | BRD4 (0.42) | BRD4BRD3BRD2CREBBPMAPT | |
| SCHEMBL16740552 | 0.71 | BRD4 (0.34) | BRD4BRD3BRD2CREBBP | |
| SCHEMBL19917016 | 0.69 | ADORA1 (0.44) | — | |
| SCHEMBL17686232 | 0.68 | BRD2 (0.37) | BRD4BRD3BRD2CREBBPTP53 | |
| SCHEMBL23459660 | 0.68 | PRMT5 (0.40) | PRMT5NOS3NOS1NOS2BACE1 | |
| SCHEMBL13347013 | 0.67 | CDK1 (0.41) | — | |
| SCHEMBL23608868 | 0.67 | PI4KA (0.44) | NOS3NOS1NOS2BACE1TP53 | |
| SCHEMBL29882352 | 0.67 | PI4KA (0.44) | NOS3NOS1NOS2BACE1TP53 | |
| SCHEMBL31210486 | 0.63 | PRMT5 (0.46) | PRMT5NOS3NOS1NOS2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412675-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-9550796-B2 | Pyrrolopyrrolone derivatives and their use as BET inhibitors | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| US-20160280719-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | NOVARTIS AG (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-3071571-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | Novartis AG (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-3004109-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| WO-2015075665-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | NOVARTIS AG (CH) | 2015-05-28 | — | — | WO | disclosed |
| WO-2014191894-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | TPMT, REN, IL5 | PRMT5 433/4885BRD4 176/4885BRD3 492/4885 |
| US-20160280719-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | BET1, PHKB, TMPO | PRMT5 1524/4885BRD4 5/4885BRD3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.